Trials / Completed
CompletedNCT00482664
The Efficacy, Safety And Toleration Of CP-866,087 In Pre-Menopausal Women With Female Sexual Arousal Disorder.
A Phase 2a Multi-Centre, Double Blind, Placebo Controlled Cross-Over Trial To Investigate The Efficacy, Safety And Toleration Of CP-866,087 In Pre-Menopausal Women Diagnosed With Female Sexual Arousal Disorder (FSAD).
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 84 (estimated)
- Sponsor
- Pfizer · Industry
- Sex
- Female
- Age
- 20 Years – 45 Years
- Healthy volunteers
- Not accepted
Summary
CP-866,087 is a non-hormonal compound, acting on the central nervous system, which has been shown in animal models to restore sexual function.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CP-866,087 | Tablets for oral administration |
| DRUG | CP-866,087 | Tablets for oral administration |
| DRUG | CP-866,087 | Tablets for oral administration |
| DRUG | Placebo | Tablets for oral administration |
Timeline
- Start date
- 2007-07-01
- Primary completion
- 2008-09-01
- Completion
- 2008-10-01
- First posted
- 2007-06-05
- Last updated
- 2010-11-01
Locations
12 sites across 5 countries: Australia, Denmark, Norway, South Africa, Sweden
Source: ClinicalTrials.gov record NCT00482664. Inclusion in this directory is not an endorsement.